Latest News and Press Releases

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American...

IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b...

Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis...

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North SydneyRecruitment to open this month at Frankston Hospital, VictoriaFurther site to follow at Curie Oncology,...

Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Stelara (Ustekinumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's...

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Tecentriq (Atezolizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study...

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...